Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 2
2004 6
2005 6
2006 8
2007 13
2008 15
2009 18
2010 21
2011 21
2012 16
2013 12
2014 11
2015 5
2016 5
2017 8
2018 4
2019 9
2020 13
2021 12
2022 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

195 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.
Eggermont AMM, Blank CU, Mandalà M, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, van Akkooi ACJ, Krepler C, Ibrahim N, Marreaud S, Kicinski M, Suciu S, Robert C; EORTC Melanoma Group. Eggermont AMM, et al. Lancet Oncol. 2021 May;22(5):643-654. doi: 10.1016/S1470-2045(21)00065-6. Epub 2021 Apr 12. Lancet Oncol. 2021. PMID: 33857412 Clinical Trial.
Les études post-inscriptions en France, quels enjeux pour les dispositifs médicaux.
Levesque K, Coqueblin C, Guillot B; et les participants à la table ronde N°3 de Giens XXIX; Aubourg L, Avouac B, Carbonneil C, Cucherat M, Descamps-Mandine P, Hanoka S, Goldberg M, Josseran A, Parquin F, Pitel S, Ratignier C, Sechoy O, Szwarcenstein K, Tanti A, Teiger E, Thevenet N. Levesque K, et al. Among authors: guillot b. Therapie. 2014 Jul-Aug;69(4):303-12. doi: 10.2515/therapie/2014047. Therapie. 2014. PMID: 27393225 French. No abstract available.
Drug-induced acneiform eruption.
Du-Thanh A, Kluger N, Bensalleh H, Guillot B. Du-Thanh A, et al. Among authors: guillot b. Am J Clin Dermatol. 2011 Aug 1;12(4):233-45. doi: 10.2165/11588900-000000000-00000. Am J Clin Dermatol. 2011. PMID: 21668032 Review.
[Monoclonal antibodies: also for dermatologists!].
Du-Thanh A, Guillot B. Du-Thanh A, et al. Among authors: guillot b. Med Sci (Paris). 2019 Dec;35(12):1017-1021. doi: 10.1051/medsci/2019201. Epub 2020 Jan 6. Med Sci (Paris). 2019. PMID: 31903911 Free article. Review. French.
PELVIS Syndrome.
Girard C, Bigorre M, Guillot B, Bessis D. Girard C, et al. Among authors: guillot b. Arch Dermatol. 2006 Jul;142(7):884-8. doi: 10.1001/archderm.142.7.884. Arch Dermatol. 2006. PMID: 16847205 Review.
Myasthenia Gravis Induced by Immune Checkpoint Inhibitors.
Becquart O, Lacotte J, Malissart P, Nadal J, Lesage C, Guillot B, Du Thanh A. Becquart O, et al. Among authors: guillot b. J Immunother. 2019 Oct;42(8):309-312. doi: 10.1097/CJI.0000000000000278. J Immunother. 2019. PMID: 31246640 Review.
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.
Bottomley A, Coens C, Mierzynska J, Blank CU, Mandalà M, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Puig S, Ascierto PA, Larkin J, Lorigan PC, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, van Akkooi ACJ, Krepler C, Ibrahim N, Marreaud S, Kicinski M, Suciu S, Robert C, Eggermont AMM; EORTC Melanoma Group. Bottomley A, et al. Lancet Oncol. 2021 May;22(5):655-664. doi: 10.1016/S1470-2045(21)00081-4. Epub 2021 Apr 12. Lancet Oncol. 2021. PMID: 33857414 Clinical Trial.
Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced basal cell carcinoma, after failure or intolerance to sonic Hedgehog inhibitors: UNICANCER AcSé NIVOLUMAB trial.
Véron M, Chevret S, Grob JJ, Beylot-Barry M, Saiag P, Fléchon A, You B, Maubec E, Jouary T, Toulemonde E, Jamme P, Gambotti L, Lamrani-Ghaouti A, Dupuy A, Lebbe C, Seguin NB, Houede N, Leccia MT, Le Du F, de Pontville M, Gaudy-Marquestre C, Guillot B, Simon C, Marabelle A, Mortier L. Véron M, et al. Among authors: guillot b. Eur J Cancer. 2022 Dec;177:103-111. doi: 10.1016/j.ejca.2022.09.013. Epub 2022 Oct 11. Eur J Cancer. 2022. PMID: 36335780 Clinical Trial.
195 results